Education
About Us
Working with TipRanks
Follow Us
LeonaBio (LONA)
NASDAQ:LONA
LONA Stock Chart & Stats
$9.92
-$0.02(-3.33%)
At close: 4:00 PM EST
$9.92
-$0.02(-3.33%)
Day’s Range― - ―
52-Week Range$2.19 - $14.21
Previous CloseN/A
VolumeN/A
Average Volume (3M)41.47K
Market Cap
$92.61M
Enterprise Value$18.41M
Total Cash (Recent Filing)$25.23M
Total Debt (Recent Filing)$912.00K
Price to Earnings (P/E)―
Beta1.96
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,335,913
10 Day Avg. Volume36,543
30 Day Avg. Volume41,474
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-26.84
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$10.00Price Target Upside0.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentATH-1105 has demonstrated a favorable safety profile and was well-tolerated in a Phase 1 study, supporting continued clinical development.
Financial StabilityThere is now sufficient cash runway to support operations through the data readout following the company's restructuring and downsizing.
Regulatory EnvironmentThe development pathway for ALS is attractive due to the FDA's flexibility and recent accelerated approval of Tofersen using Nf-L as a surrogate biomarker.
Bears Say
Financial ChallengesGiven the discontinuation of fosgonimeton, ATHA has significantly restructured and reduced future operating expenses, indicating financial challenges.
Partnership ChallengesThe company is unlikely to advance the program without a partner, and a partnership is unlikely to materialize due to the challenging ALS space and negative data for prior lead asset.
Strategic UncertaintyA strategic transaction for ATHA could ultimately result, but visibility on when and with whom is low, leading analysts to recommend looking elsewhere for growth opportunities.
LeonaBio News
LONA FAQ
What was LeonaBio’s price range in the past 12 months?
LeonaBio lowest stock price was $2.19 and its highest was $14.21 in the past 12 months.
What is LeonaBio’s market cap?
LeonaBio’s market cap is $92.61M.
When is LeonaBio’s upcoming earnings report date?
LeonaBio’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were LeonaBio’s earnings last quarter?
Currently, no data Available
Is LeonaBio overvalued?
According to Wall Street analysts LeonaBio’s price is currently Undervalued.
Does LeonaBio pay dividends?
LeonaBio does not currently pay dividends.
What is LeonaBio’s EPS estimate?
LeonaBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LeonaBio have?
LeonaBio has 9,335,913 shares outstanding.
What happened to LeonaBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LeonaBio?
Currently, no hedge funds are holding shares in LONA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LeonaBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (0.81% Upside)
$10.00 (0.81% Upside)
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.12%
12-Months-Change
Fundamentals
Return on Equity
-107.06%
Trailing 12-Months
Asset Growth
-65.18%
Trailing 12-Months
Company Description
LeonaBio
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
LONA Stock 12 Month Forecast
Average Price Target
$10.00
▲(0.81% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---